Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.
|Videos|August 19, 2016
Dr. Federman on Challenges With Treating AYA Patients With Sarcoma
Author(s)Noah Federman, MD
Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.
Advertisement
Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
5